Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study
ObjectiveThis study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).MethodsFifty-five patients with pMN treated with obinutuzumab were respectively enrolled in this study. Clinical and immunologic...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1650054/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849231599983394816 |
|---|---|
| author | Xi Cheng Zhen-feng Zheng Yan Qi Xin Cao Xi-qian Gao Ying-xin Fang Li Wei Wen-ya Shang Tie-kun Yan Jun-ya Jia Peng-cheng Xu Qiu-hua Gu |
| author_facet | Xi Cheng Zhen-feng Zheng Yan Qi Xin Cao Xi-qian Gao Ying-xin Fang Li Wei Wen-ya Shang Tie-kun Yan Jun-ya Jia Peng-cheng Xu Qiu-hua Gu |
| author_sort | Xi Cheng |
| collection | DOAJ |
| description | ObjectiveThis study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).MethodsFifty-five patients with pMN treated with obinutuzumab were respectively enrolled in this study. Clinical and immunological response, renal function and adverse events were assessed throughout the follow-up period between patients receiving obinutuzumab as initial therapy and alternative therapy.ResultsThe study included 40 patients receiving obinutuzumab as an alternative therapy, and 15 patients receiving it as an initial therapy. During a follow up of 13.0(10.0, 18.0) months after obinutuzumab treatment, 23/25(92.0%) patients achieved immunological remission. 46/55(83.6%) patients achieved clinical remission (including 40.0% of PR and 43.6% of CR), with significantly reduced proteinuria and increased serum albumin. Patients with obinutuzumab as either the initial or alternative treatment showed similar clinical response (85.0 vs. 80.0%, P=0.692). 13 out of 18 patients (72.2%) with impaired kidney function (eGFR <60 mL/min/1.73 m²) also showed significant response to obinutuzumab, along with eGFR increasing from 35.3 to 47.6 mL/min/1.73m². Furthermore, obinutuzumab also had a comparable efficiency in patients without response to previous rituximab treatment and patients with negative anti-PLA2R antibody. More patients in the initial therapy group had infusion-related reactions (33.3 vs. 15.0%, P=0.149), while severe infections were all occurred in the alternative therapy group, particularly those with a history of long-term immunosuppressive therapy.ConclusionsObinutuzumab, used as both initial and alternative therapy, can induce significant clinical response in patients with pMN, implying its potentially promising therapeutic effect on pMN. |
| format | Article |
| id | doaj-art-df0375ec2e9f47199d58e86c8502c909 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-df0375ec2e9f47199d58e86c8502c9092025-08-21T05:27:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16500541650054Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective studyXi Cheng0Zhen-feng Zheng1Yan Qi2Xin Cao3Xi-qian Gao4Ying-xin Fang5Li Wei6Wen-ya Shang7Tie-kun Yan8Jun-ya Jia9Peng-cheng Xu10Qiu-hua Gu11Department of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Tianjin Medical University General Hospital Airport Hospital, Tianjin, ChinaDepartment of Nephrology, Tianjin Medical University General Hospital Airport Hospital, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaDepartment of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, ChinaObjectiveThis study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).MethodsFifty-five patients with pMN treated with obinutuzumab were respectively enrolled in this study. Clinical and immunological response, renal function and adverse events were assessed throughout the follow-up period between patients receiving obinutuzumab as initial therapy and alternative therapy.ResultsThe study included 40 patients receiving obinutuzumab as an alternative therapy, and 15 patients receiving it as an initial therapy. During a follow up of 13.0(10.0, 18.0) months after obinutuzumab treatment, 23/25(92.0%) patients achieved immunological remission. 46/55(83.6%) patients achieved clinical remission (including 40.0% of PR and 43.6% of CR), with significantly reduced proteinuria and increased serum albumin. Patients with obinutuzumab as either the initial or alternative treatment showed similar clinical response (85.0 vs. 80.0%, P=0.692). 13 out of 18 patients (72.2%) with impaired kidney function (eGFR <60 mL/min/1.73 m²) also showed significant response to obinutuzumab, along with eGFR increasing from 35.3 to 47.6 mL/min/1.73m². Furthermore, obinutuzumab also had a comparable efficiency in patients without response to previous rituximab treatment and patients with negative anti-PLA2R antibody. More patients in the initial therapy group had infusion-related reactions (33.3 vs. 15.0%, P=0.149), while severe infections were all occurred in the alternative therapy group, particularly those with a history of long-term immunosuppressive therapy.ConclusionsObinutuzumab, used as both initial and alternative therapy, can induce significant clinical response in patients with pMN, implying its potentially promising therapeutic effect on pMN.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1650054/fullmembranous nephropathyobinutuzumabrituximabanti-phospholipase A2 receptor antibodyrenal function |
| spellingShingle | Xi Cheng Zhen-feng Zheng Yan Qi Xin Cao Xi-qian Gao Ying-xin Fang Li Wei Wen-ya Shang Tie-kun Yan Jun-ya Jia Peng-cheng Xu Qiu-hua Gu Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study Frontiers in Immunology membranous nephropathy obinutuzumab rituximab anti-phospholipase A2 receptor antibody renal function |
| title | Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study |
| title_full | Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study |
| title_fullStr | Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study |
| title_full_unstemmed | Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study |
| title_short | Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study |
| title_sort | efficacy and safety of obinutuzumab in primary membranous nephropathy a real world retrospective study |
| topic | membranous nephropathy obinutuzumab rituximab anti-phospholipase A2 receptor antibody renal function |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1650054/full |
| work_keys_str_mv | AT xicheng efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT zhenfengzheng efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT yanqi efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT xincao efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT xiqiangao efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT yingxinfang efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT liwei efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT wenyashang efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT tiekunyan efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT junyajia efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT pengchengxu efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy AT qiuhuagu efficacyandsafetyofobinutuzumabinprimarymembranousnephropathyarealworldretrospectivestudy |